CN106728336A - A kind of Chinese medicine composition and its preparation method and application - Google Patents
A kind of Chinese medicine composition and its preparation method and application Download PDFInfo
- Publication number
- CN106728336A CN106728336A CN201710083806.5A CN201710083806A CN106728336A CN 106728336 A CN106728336 A CN 106728336A CN 201710083806 A CN201710083806 A CN 201710083806A CN 106728336 A CN106728336 A CN 106728336A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- weight portion
- grams
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 19
- 230000001154 acute effect Effects 0.000 claims abstract description 19
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 18
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 18
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 18
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 18
- 241000405414 Rehmannia Species 0.000 claims abstract description 18
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 18
- 206010043595 Thrombophlebitis superficial Diseases 0.000 claims abstract description 16
- 238000001914 filtration Methods 0.000 claims abstract description 12
- 210000003141 lower extremity Anatomy 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- 238000011282 treatment Methods 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 18
- 241000123069 Ocyurus chrysurus Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical group C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 claims 2
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 abstract description 6
- 108010049003 Fibrinogen Proteins 0.000 abstract description 3
- 102000008946 Fibrinogen Human genes 0.000 abstract description 3
- 229940012952 fibrinogen Drugs 0.000 abstract description 3
- 241001107098 Rubiaceae Species 0.000 abstract description 2
- 230000010354 integration Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 238000005119 centrifugation Methods 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 208000001297 phlebitis Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000001732 thrombotic effect Effects 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 239000003154 D dimer Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000252185 Cobitidae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- -1 by identification Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008320 venous blood flow Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to field of medicaments, more particularly to a kind of Chinese medicine composition for treating acute hindlimb superficial thrombophlebitis and its preparation method and application.It with 9~15 weight portion madders, 9~15 weight portion hairyvein agrimonies, 6~12 weight portion dried rhizome of rehmannia, 6~12 weight portion radix paeoniae rubrathe, 6~12 weight portion root barks of tree peony, 3~4 weight portion pseudo-ginseng is raw material that Chinese medicine composition of the invention is made of.Its preparation method includes：The Chinese medicine of formula ratio is weighed, is added water to decoct together and is extracted, merged and decoct extract solution, filtering, concentration, centrifugation is dried, and dry extract is obtained.Clinical test shows：Chinese medicine composition of the invention can improve hemorheology in patients, reduce fibrinogen, DD aggressiveness, improve TCM syndrome integration, with prospect in medicine.
Description
Technical field
The invention belongs to field of medicaments, more particularly to a kind of Chinese medicine composition and its preparation method and application.
Background technology
Acute thrombotic superficial phlebitis (Superficial Thrombophlebitis) is clinically common Peripheral blood
One of pipe disease, is thrombotic, the inflammatory lesion for betiding limbs superficial vein.Men and women can suffer from, and be apt to occur in four limbs, next to that
Chest and abdomen wall, minority is in migrans breaking-out, is risen one after another, and can alternately be fallen ill in many places.Clinical table be superficial vein at rubescent, swelling,
It is scorching hot, there is hard tubercle or rope bar, have obvious tenderness and pain, after acute stage, rope bar is hardened, local skin
Pigmentation.The categories such as the category traditional Chinese medical science " Chi Mai " " acute thrombophlebitis " " yellow loach carbuncle ".Modern medicine thinks that superficial thrombophlebitis is vein
Inflammation in chamber is simultaneously with thrombosis.Thrombosis refers to blood in the case where stream mode is become, one kind of hemostatic mechanism excessive activation
Pathology final result.Thrombosis is retarded by silt by venous blood flow more, the damage of wall of vein and blood viscosity increase caused.Thrombus shape
It is related to abnormal vascular intimal surface, the interaction between blood platelet and the clotting factor of activation, the life of its result into process
Into localization, relatively stable " mechanicalness " embolus, then there is slow dissolving in the presence of fibrinolytic system.Modernology
Person thinks, for the understanding of this disease, often with damp-heat accumulation, hemostasis impatency is main pathogenesis, and ruling by law promoting blood circulation and removing blood stasis is used in treatment
Based on treatment.
Several common methods such as the acute thrombotic main anti-freezing of superficial phlebitis western medical treatment, drop fibre, anti-inflammatory.Though these methods
So there is certain therapeutic effect, but clinical practice also has many indications and contraindication.These treatment methods of doctor trained in Western medicine are all
There is the side effect of bleeding.And research of the traditional Chinese medicine to superficial thrombophlebitis, it is mostly after phlebitis generation, to sequelae
Improvement aspect, therefore, need a kind of Chinese medicine for treating acute thrombotic superficial phlebitis of exploitation badly.
The content of the invention
The purpose of the present invention aim to provide it is a kind of can effectively, low toxicity treat the Chinese medicine composition of acute thrombotic superficial phlebitis
And its preparation method and application..
Specifically, it is described the invention provides a kind of Chinese medicine composition for treating acute hindlimb superficial thrombophlebitis
Chinese medicine composition is red with 9~15 weight portion madders, 9~15 weight portion hairyvein agrimonies, 6~12 weight portion dried rhizome of rehmannia, 6~12 weight portions
Chinese herbaceous peony, 6~12 weight portion root barks of tree peony, 3~4 weight portion pseudo-ginseng are made up of raw material.
In a preference, the Chinese medicine composition is prepared from by raw material of the Chinese medicine of following weight portion：Madder 15
Part, 15 parts of hairyvein agrimony, 12 parts of the dried rhizome of rehmannia, 12 parts of the radix paeoniae rubrathe, 12 parts of the root bark of tree peony, 4 parts of pseudo-ginseng.
The second aspect of the present invention there is provided a kind of Chinese medicine composition for treating acute hindlimb superficial thrombophlebitis
Preparation method, it is made dry extract, comprises the following steps as raw material with the Chinese medicine using water extraction：
A) madder, hairyvein agrimony, the dried rhizome of rehmannia, the radix paeoniae rubrathe, the root bark of tree peony, the pseudo-ginseng of formula ratio are weighed；
B) add water to cook twice, decoct 1 hour every time, the volume that adds water every time is 8 times of medicinal material gross weight, merge twice
Decocting liquid, filtering；
C) relative density for concentrating the filtrate to determine at room temperature is 1.20, is then 60%~95% with volume fraction
Ethanol water alcohol precipitation；
D) it is 1.36 to reclaim ethanol and be concentrated into the relative density for determining at room temperature, obtains medicinal extract, is vacuum dried, and obtains dry leaching
Cream.
The third aspect of the present invention there is provided a kind of Chinese medicine composition for treating acute hindlimb superficial thrombophlebitis
Preparation method, it is made dry extract, comprises the following steps as raw material with the Chinese medicine using alcohol extracting method：
A) madder, hairyvein agrimony, the dried rhizome of rehmannia, the radix paeoniae rubrathe, the root bark of tree peony, the pseudo-ginseng of formula ratio are weighed；
B) plus volume fraction be 60%~95% ethanol water, refluxing extraction twice, 1.5 hours every time, each institute
It it is 8~10 times of medicinal material gross weight with the volume of ethanol water；
C) merge alcohol extract, ethanol is recovered under reduced pressure, obtain medicinal extract, be vacuum dried, obtain dry extract.
In a preference, the vacuum drying temperature of medicinal extract is 60 DEG C~80 DEG C.
In another preference, the vacuum drying temperature of medicinal extract is 70 DEG C.
Present invention also offers the Chinese medicine composition in the medicine for preparing treatment acute hindlimb superficial thrombophlebitis
Application.
In a preference, described medicine is granule, tablet, capsule, pill or pill.
The details of various aspects of the present invention will be able to detailed description in subsequent chapters and sections.By hereafter and claim
Description, the features of the present invention, purpose and advantage will become apparent from.
Specific embodiment
With reference to specific embodiment, the present invention is expanded on further.It should be understood that these embodiments are merely to illustrate the present invention
Rather than limitation the scope of the present invention.Reagent and raw material used in the following example can be bought by commercial sources and obtained
.The experimental technique of unreceipted actual conditions in the following example, generally according to normal condition or according to proposed by manufacturer
Condition.Unless otherwise defined, all specialties used in text and scientific words and meaning familiar to one skilled in the art institute
Justice is identical.Additionally, during any method similar to described content or impartial and material all can be applied to the inventive method.Wen Zhong
Described preferable implementation only presents a demonstration with material and is used.
The features described above that the present invention is mentioned, or the feature that embodiment is mentioned can be in any combination.Patent specification is taken off
The all features shown can be used in combination with any combinations thing form, and each feature disclosed in specification can provide phase with any
The alternative characteristics substitution of same, impartial or similar purpose.Therefore except there is special instruction, disclosed feature is only impartial or similar
The general example of feature.
Madder used, hairyvein agrimony, the dried rhizome of rehmannia, the radix paeoniae rubrathe, the root bark of tree peony, pseudo-ginseng meet Chinese Pharmacopoeia 2005 editions in following embodiments
Relevant every regulation under one each medicinal material of text.Each medicinal material is thrown by working processes such as net system, cutting, processing, crushing
Before material, by identification, ingredients material object is consistent with title, and quality meets NF standard (specific Med Mat Appreciation method ginseng
Performed according to standards of pharmacopoeia).
Embodiment 1
Weigh 15 grams of madder, 15 grams of hairyvein agrimony, 12 grams of the dried rhizome of rehmannia, 12 grams of the radix paeoniae rubrathe, 12 grams of the root bark of tree peony, 4 grams of pseudo-ginseng；
Add water to cook twice, decoct 1 hour every time, add water 216ml every time；Merge decocting liquid twice, filtering；
The relative density for concentrating the filtrate to be determined at 25 DEG C is 1.20, then water-soluble with the ethanol that volume fraction is 70%
Liquid carries out alcohol precipitation；
It is 1.36 to reclaim ethanol and be concentrated into the relative density determined at 25 DEG C, and finally vacuum is done under conditions of 70 DEG C
It is dry, obtain dry extract 4g.
Embodiment 2
Weigh 30 grams of madder, 30 grams of hairyvein agrimony, 15 grams of the dried rhizome of rehmannia, 15 grams of the radix paeoniae rubrathe, 15 grams of the root bark of tree peony, 4 grams of pseudo-ginseng；
Add water to cook twice, decoct 1 hour every time, add water 216ml every time；Merge decocting liquid twice, filtering；
The relative density for concentrating the filtrate to be determined at 25 DEG C is 1.20, then water-soluble with the ethanol that volume fraction is 70%
Liquid carries out alcohol precipitation；
It is 1.36 to reclaim ethanol and be concentrated into the relative density determined at 25 DEG C, and finally vacuum is done under conditions of 70 DEG C
It is dry, obtain dry extract 4g.
Embodiment 3
Weigh 15 grams of madder, 30 grams of hairyvein agrimony, 12 grams of the dried rhizome of rehmannia, 15 grams of the radix paeoniae rubrathe, 12 grams of the root bark of tree peony, 4 grams of pseudo-ginseng；
Add water to cook twice, decoct 1 hour every time, add water 216ml every time；Merge decocting liquid twice, filtering；
The relative density for concentrating the filtrate to be determined at 25 DEG C is 1.20, then water-soluble with the ethanol that volume fraction is 70%
Liquid carries out alcohol precipitation；
It is 1.36 to reclaim ethanol and be concentrated into the relative density determined at 25 DEG C, and finally vacuum is done under conditions of 70 DEG C
It is dry, obtain dry extract 4g.
Embodiment 4
Weigh 30 grams of madder, 30 grams of hairyvein agrimony, 12 grams of the dried rhizome of rehmannia, 15 grams of the radix paeoniae rubrathe, 12 grams of the root bark of tree peony, 2 grams of pseudo-ginseng；
Add water to cook twice, decoct 1 hour every time, add water 216ml every time；Merge decocting liquid twice, filtering；
The relative density for concentrating the filtrate to be determined at 25 DEG C is 1.20, then water-soluble with the ethanol that volume fraction is 70%
Liquid carries out alcohol precipitation；
It is 1.36 to reclaim ethanol and be concentrated into the relative density determined at 25 DEG C, and finally vacuum is done under conditions of 70 DEG C
It is dry, obtain dry extract 4g.
Embodiment 5
Weigh 30 grams of madder, 15 grams of hairyvein agrimony, 12 grams of the dried rhizome of rehmannia, 15 grams of the radix paeoniae rubrathe, 12 grams of the root bark of tree peony, 2 grams of pseudo-ginseng；
Add water to cook twice, decoct 1 hour every time, add water 216ml every time；Merge decocting liquid twice, filtering；
The relative density for concentrating the filtrate to be determined at 25 DEG C is 1.20, then water-soluble with the ethanol that volume fraction is 70%
Liquid carries out alcohol precipitation；
It is 1.36 to reclaim ethanol and be concentrated into the relative density determined at 25 DEG C, and finally vacuum is done under conditions of 70 DEG C
It is dry, obtain dry extract 4g.
Relative density is 1.4；It is centrifuged 1 minute under the rotating speed of 4000r/min；In 70 DEG C of vacuum drying, dry extract is obtained.
Embodiment 6
Weigh 300 grams of madder, 300 grams of hairyvein agrimony, 150 grams of the dried rhizome of rehmannia, 150 grams of the radix paeoniae rubrathe, 150 grams of the root bark of tree peony, 40 grams of pseudo-ginseng；
Add water to cook twice, decoct 1 hour every time, add water 28.8L every time；Merge decocting liquid twice, filtering；
The relative density for concentrating the filtrate to be determined at 25 DEG C is 1.20, then water-soluble with the ethanol that volume fraction is 70%
Liquid carries out alcohol precipitation；
It is 1.36 to reclaim ethanol and be concentrated into the relative density determined at 25 DEG C, and finally vacuum is done under conditions of 70 DEG C
It is dry, obtain dry extract 480g.
Embodiment 7
Weigh 300 grams of madder, 300 grams of hairyvein agrimony, 150 grams of the dried rhizome of rehmannia, 150 grams of the radix paeoniae rubrathe, 150 grams of the root bark of tree peony, 40 grams of pseudo-ginseng；
Add water to cook twice, decoct 1 hour every time, add water 28.8L every time；Merge decocting liquid twice, filtering；
The relative density for concentrating the filtrate to be determined at 25 DEG C is 1.20, then water-soluble with the ethanol that volume fraction is 90%
Liquid carries out alcohol precipitation；
It is 1.36 to reclaim ethanol and be concentrated into the relative density determined at 25 DEG C, and finally vacuum is done under conditions of 80 DEG C
It is dry, obtain dry extract 480g.
Embodiment 8
Weigh 300 grams of madder, 300 grams of hairyvein agrimony, 150 grams of the dried rhizome of rehmannia, 150 grams of the radix paeoniae rubrathe, 150 grams of the root bark of tree peony, 40 grams of pseudo-ginseng；
Add water to cook twice, decoct 1 hour every time, add water 28.8L every time；Merge decocting liquid twice, filtering；
The relative density for concentrating the filtrate to be determined at 25 DEG C is 1.20, then water-soluble with the ethanol that volume fraction is 70%
Liquid carries out alcohol precipitation；
It is 1.36 to reclaim ethanol and be concentrated into the relative density determined at 25 DEG C, and finally vacuum is done under conditions of 60 DEG C
It is dry, obtain dry extract 460g.
Embodiment 9
Dry extract 150g (equivalent to crude drug 1000g) is taken, starch 80g, dextrin 120g, sodium carboxymethyl starch 20g is added, with
Used as adhesive, softwood processed crosses the pelleting of 14 mesh sieves to 50% ethanol, dries, and adds appropriate talcum powder compressing tablet, plain piece bag film
Clothing, obtains final product the tablet prepared using the Chinese medicine composition.
Embodiment 10
Take dry extract common 230g, lactose 480g, mannitol 100g, cross-linked pvp 100g, 95% appropriate amount of ethanol, magnesium stearate
15g.It is tabletted, obtain final product the Solide dispersion tablets prepared using the Chinese medicine composition.
Embodiment 11
Dry extract 200g is taken, by 1:2 ratios add Macrogol 4000, mix, heating melting, and closed and insulation is 80
DEG C, instill in 0~10 DEG C of atoleine, dripping pill is collected, drip is most and wipes coolant, obtains final product and is prepared using the Chinese medicine composition
Dripping pill.
Embodiment 12
Dry extract 200g, lactose 90g, magnesium stearate 1.5g are taken, large stretch of (piece weight 2g) is pressed after mixing, this pre- compressing tablet is being shaken
Crushed in pendulum-type granule, whole grain, dispensed with aluminum-plastic composite membrane, obtain final product the granule prepared using the Chinese medicine composition.
Embodiment 13
Dry extract 200g is taken, starch 150g is added, mixed, cross No. seven sieves, it is encapsulated, obtain final product using the Chinese medicine composition
The capsule of preparation.
Embodiment 14
20g beeswaxs, 500g soybean oils are heated to about 50 DEG C, stirring treats that it is melted completely, that is, are made beeswax oil；Take dry leaching
Cream 500g, adds in beeswax oil, stirs evenly；Sieved with colloid mill wet pulverizing, be made oil suspension, it is standby；300g gelatin is taken to add
Enter suitable quantity of water, be allowed to water swelling, added after suitable 150g glycerine is heated in the gelatin for having expanded, be heated with stirring to melting；Will
Shell glue filtering suction, removes part moisture content and foam, using rotary-die type soft capsule manufacturing machine, by deployed content pressure
Enter shell film, be wrapped in and wherein form soft capsule.The greasy dirt of capsule surface is washed away, it is 25-30 DEG C to be placed in temperature, and relative humidity is
Dried in the baking oven of 20-25%, obtain final product the soft capsule prepared using the Chinese medicine composition.
The beneficial effect of medicine of the present invention is expanded on further below by clinical test example.
Clinical trial data
1 clinical data and method
1.1 clinical datas
All patients are June 1 year January in 2011 in vascular disorders section of the court out-patient, meet《Week
Enclose vascular diseases combination of Chinese tradiational and Western medicine diagnostics》The diagnostic criteria of superficial thrombophlebitis acute stage.Totally 120, by random digit
Table is divided into observation group and control group.Man 28, female 32 in observation group 60；54 1 70 years old age is average (65.2 soil 9.2)
Year.Man 30 in control group 60, female 30,51-70 years old ages, average (62.6 soil 11.5) year.2 groups of Genders, ages
It is statistically analyzed, difference there are no significant difference (P>0.05), with comparativity.
1.2 treatment methods
The oral train of thought Shutong granules of control group, 3 times a day, every time 1 bag (authentication code:Chinese medicines quasi-word Z19991025, rule
Lattice:Per packed 20g, 15 bags/box).Treatment group take the present composition (by embodiment 1 prepare oral liquid formulations), 2 times/
Day.2 weeks 1 courses for the treatment of 2, two groups are observed 2 courses for the treatment of.
1.3 sight case indexs
Patient carries out measure and the assessment of following index after 2 courses for the treatment of of m seq and treatment after being admitted to hospital：Tcm syndrome is accumulated
Divide and efficacy evaluation；Fibrinogen (FIB), thrombin time (TT), prothrombin time (PT), partial prothrombinase time
(APTT), D dimer (DD).Meanwhile, two groups are observed change and the side reaction situations such as stool and urine and hepatic and renal function simultaneously.
1.4 statistical methods
Statistical analysis is carried out using SPSS10.0 softwares.Measurement data is represented with (x soil s), compares before and after treatment and examined with t
Test, comparitive study is analyzed using Ridit.
2 results
2.1 Chinese medicine syndrome integrals are evaluated, and are shown in Table 1
TCM syndrome integral contrast (x soil s) before and after 1 two groups of treatments of table
Note：Compare before and after two groups of treatments, * p<0.05**p<0.01, observation group and control group compare, #p<0.05##p<
0.01
Compare with before treatment, two groups of patient's TCM syndrome integrations have conspicuousness to decline p after treatment<0.01, observation group is excellent
In control group, p<0.05.
2.2 Blood Coagulation situations of change compare, and are shown in Table 2
2 two groups of associated coagulation functional parameter situations of change of table compare
Note：With this group before treatment, * P ＜ 0.05；Compare with after control group treatment, #P ＜ 0.05
2.3 clinical efficacies are evaluated, and are shown in Table 3
3 two groups of Clinical efficacy comparisons (example %) of table
Note：Observation group and control group compare, * p<0.05**p<0.01
Overall clinical efficacy rate observation group is 91.67%, and control group is 81.67%, is compared after two groups of treatments, and difference has significantly
Property meaning, treatment group be better than control group (P<0.05).
Blood rheology parameter change, is shown in Table 4 before and after 2.4 two groups of treatments
Hemorheology changes unit (mmol/L) (x ± s) before and after 4 two groups of treatments of table
Note:Compare * p before and after two groups of treatments<0.05**p<0.01, observation group and control group compare, #p<0.05##p<
0.01。
Compare with before treatment, two groups of patient whole blood's specific viscosities after treatment, plasma viscosity, packed cell volume (%), fiber
Proteinogen has conspicuousness to decline, p<0.05 or p<0.01, to compare between group, index observing group in part is better than control group, p after treatment
<0.05。
2.5 adverse drug reactions, safety detection:Adverse reaction is not found during treatment patients, it is every before and after treatment
Position patient enter the inspection such as promoting circulation of blood, urine, stool routine examination and hepatic and renal function, electrocardiogram do not have found that it is likely that it is directly relevant with treatment different
Often change.
2.7 conclusions：The present composition has improves hemorheology in patients, reduces fibrinogen, DD aggressiveness, improves
TCM syndrome is integrated, and improves the effect of clinical treatment curative effect.
Claims (8)
1. a kind of Chinese medicine composition for treating acute hindlimb superficial thrombophlebitis, it is characterised in that：It is alizarin with 9~15 weight portions
Grass, 9~15 weight portion hairyvein agrimonies, 6~12 weight portion dried rhizome of rehmannia, 6~12 weight portion radix paeoniae rubrathe, 6~12 weight portion root barks of tree peony, 3~4 weight
Part pseudo-ginseng is made up of raw material.
2. the Chinese medicine composition of acute hindlimb superficial thrombophlebitis is treated as claimed in claim 1, it is characterised in that below
The Chinese medicine of row weight portion is prepared from for raw material：15 parts of madder, 15 parts of hairyvein agrimony, 12 parts of the dried rhizome of rehmannia, 12 parts of the radix paeoniae rubrathe, the root bark of tree peony 12
Part, 4 parts of pseudo-ginseng.
3. it is a kind of it is as claimed in claim 1 treatment acute hindlimb superficial thrombophlebitis Chinese medicine composition preparation method,
Characterized in that, being made dry extract using water extraction as raw material with the Chinese medicine, comprise the following steps：
A) madder, hairyvein agrimony, the dried rhizome of rehmannia, the radix paeoniae rubrathe, the root bark of tree peony, the pseudo-ginseng of formula ratio are weighed；
B) add water to cook twice, decoct 1 hour every time, the volume that adds water every time is 8 times of medicinal material gross weight, merge decocting twice
Liquid, filtering；
C) relative density for concentrating the filtrate to determine at room temperature is 1.20, then with the ethanol that volume fraction is 60%~95%
Aqueous solution alcohol precipitation；
D) it is 1.36 to reclaim ethanol and be concentrated into the relative density for determining at room temperature, obtains medicinal extract, is vacuum dried, and obtains dry extract.
4. it is a kind of it is as claimed in claim 1 treatment acute hindlimb superficial thrombophlebitis Chinese medicine composition preparation method,
Characterized in that, being made dry extract using alcohol extracting method as raw material with the Chinese medicine, comprise the following steps：
A) madder, hairyvein agrimony, the dried rhizome of rehmannia, the radix paeoniae rubrathe, the root bark of tree peony, the pseudo-ginseng of formula ratio are weighed；
B) plus ethanol water that volume fraction is 60%~95%, refluxing extraction twice, 1.5 hours every time, every time second used
The volume of alcohol solution is 8~10 times of medicinal material gross weight；
C) merge alcohol extract, ethanol is recovered under reduced pressure, obtain medicinal extract, be vacuum dried, obtain dry extract.
5. as described in claim 3 or 4 treatment acute hindlimb superficial thrombophlebitis Chinese medicine composition preparation method, its
It is characterised by, the vacuum drying temperature of medicinal extract is 60 DEG C~80 DEG C.
6. the preparation method of the Chinese medicine composition of acute hindlimb superficial thrombophlebitis is treated as claimed in claim 5, and it is special
Levy and be, the vacuum drying temperature of medicinal extract is 70 DEG C.
7. Chinese medicine composition as claimed in claim 1 prepare treatment acute hindlimb superficial thrombophlebitis medicine in should
With.
8. application as claimed in claim 7, it is characterised in that described medicine be granule, tablet, capsule, pill or
Pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710083806.5A CN106728336B (en) | 2017-02-16 | 2017-02-16 | Traditional Chinese medicine composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710083806.5A CN106728336B (en) | 2017-02-16 | 2017-02-16 | Traditional Chinese medicine composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106728336A true CN106728336A (en) | 2017-05-31 |
| CN106728336B CN106728336B (en) | 2020-02-07 |
Family
ID=58958701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710083806.5A Active CN106728336B (en) | 2017-02-16 | 2017-02-16 | Traditional Chinese medicine composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106728336B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115501285A (en) * | 2022-09-23 | 2022-12-23 | 上海市中西医结合医院 | Traditional Chinese medicine composition and preparation and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1672699A (en) * | 2004-03-26 | 2005-09-28 | 哈药集团制药六厂 | Medicine for treating phlebothrombosis and thrombotic superficial phlebitis of lower limb and its prepn |
-
2017
- 2017-02-16 CN CN201710083806.5A patent/CN106728336B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1672699A (en) * | 2004-03-26 | 2005-09-28 | 哈药集团制药六厂 | Medicine for treating phlebothrombosis and thrombotic superficial phlebitis of lower limb and its prepn |
| CN100431579C (en) * | 2004-03-26 | 2008-11-12 | 哈药集团制药六厂 | Medicine for treating phlebothrombosis and thrombotic superficial phlebitis of lower limb and its prepn |
Non-Patent Citations (1)
| Title |
|---|
| 赵诚等: "清营解瘀汤治疗急性血栓性浅静脉炎临床观察", 《中医临床研究》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115501285A (en) * | 2022-09-23 | 2022-12-23 | 上海市中西医结合医院 | Traditional Chinese medicine composition and preparation and application thereof |
| CN115501285B (en) * | 2022-09-23 | 2023-09-08 | 上海市中西医结合医院 | Traditional Chinese medicine composition, preparation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106728336B (en) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103055022B (en) | Method for processing rehmannia and application for rehmannia in preparation for medicine | |
| US20120309710A1 (en) | Compound sea cucumber preparation and manufacturing method thereof | |
| CN101940740B (en) | Chinese medicinal preparation for treating anemia | |
| CN104856968B (en) | A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof | |
| CN105943615A (en) | Application of whole hemp extract in preparation of pancreatic cancer treating drug | |
| CN104774243A (en) | Eucheuma polypeptide extract, as well as preparation method and application thereof | |
| CN105816471B (en) | A kind of notoginseng total saponin compounds and its preparation method and application | |
| CN106728336A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| CN106309671B (en) | Longnan of Gansu Province Z-bungeanum Maxim extract components and preparation method thereof and detection method | |
| CN105998194A (en) | Antithrombotic medicine | |
| CN109966433A (en) | A kind of Chinese medicine composition and its preparation method and application for treating urarthritis | |
| CN105030948B (en) | A kind of new application of pharmaceutical composition and its preparation | |
| CN103520447B (en) | Externally used ointment suitable for anal fistula after operation | |
| CN101697989A (en) | Application of notoginseng and extract thereof in preparing medicaments for treating and/or preventing coronary artherosclerosis | |
| CN102293959B (en) | Anticancer traditional Chinese medicine and preparation method thereof | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN105287921A (en) | Medicinal composition for treating gastric cancer and preparation method thereof | |
| CN103720943B (en) | A kind of Chinese medicine for the treatment of gynecological bleeding and preparation method thereof | |
| CN112386654B (en) | Traditional Chinese medicine composition, extract, preparation method and application thereof | |
| CN102232982A (en) | Extract product of herba cephalanoploris effective position, preparation method thereof and purpose thereof | |
| CN108272941A (en) | A kind of Chinese medicine preparation and preparation method thereof for treating chronic chyluria | |
| CN104622987A (en) | Pharmaceutical composition for treating chronic hepatitis and liver cirrhosis and application thereof | |
| CN108785568A (en) | A kind of Chinese medicine composition and its preparation method and application for treating diabetic foot ulcer | |
| CN105147923A (en) | Traditional Chinese medicine composition for treating coronary heart disease and preparation method of traditional Chinese medicine composition | |
| CN106581102A (en) | Pharmaceutical composition for treatment of uterine myoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210301 Address after: 215123 C30 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee after: SUZHOU YOUSEEN NEW DRUG R & D Co.,Ltd. Address before: No. 230, Baoding Road, Hongkou District, Shanghai 200082 Patentee before: SHANGHAI TCM-INTEGRATED Hospital |